Modulating the RAGE-Induced Inflammatory Response: Peptoids as RAGE Antagonists.

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) pathology involves amyloid-β plaques and tau tangles, with chronic neuroinflammation playing a significant role.
• The receptor for advanced glycation end-products (RAGE) is upregulated in AD, mediating inflammatory responses through its ligands like amyloid-β.
• Current AD therapeutics do not target RAGE-mediated neuroinflammation, highlighting an unmet clinical need.

Purpose of the Study:

• To design and evaluate peptoids as novel RAGE antagonists for treating AD-associated neuroinflammation.
• To investigate the binding affinity of designed peptoids to RAGE.
• To assess the efficacy of peptoids in attenuating RAGE-mediated inflammatory responses.

Main Methods:

• Peptoids were designed to mimic amyloid-β and inhibit RAGE activation.
• Binding affinity of peptoids JPT1 and JPT1a to RAGE was determined.
• Lipopolysaccharide-induced pro-inflammatory cytokine production and RAGE cell surface expression were measured in the presence of peptoids.

Main Results:

• Peptoids JPT1 and JPT1a exhibited nanomolar binding affinity to RAGE.
• These peptoids effectively attenuated lipopolysaccharide-induced pro-inflammatory cytokine release.
• The peptoids also reduced the upregulation of RAGE cell surface expression.

Conclusions:

• Peptoid-based RAGE antagonists demonstrate potential as a therapeutic strategy for Alzheimer's disease.
• This approach may be beneficial in combating neuroinflammation in AD and other neurodegenerative diseases.
• Peptoids offer advantages such as low toxicity and blood-brain barrier permeability.